Study of Thymosin Beta 4 in Patients With Pressure Ulcers

Inclusion criteria: * Informed Consent Form signed by the patient or patient's legal representative * Inpatients and outpatients * At least 1 PU with full-thickness skin loss and no joint capsule or bone exposure * Surface area between 5 and 70 cm2 * Ulcer present and stable for at least 1 month before enrollment Exclusion Criteria: * Use of any experimental drug, or participation in any clinical study, within the 60 days before enrollment * Use of immunotherapy, or cytotoxic chemotherapy within the 60 days before enrollment. Systemic steroids not allowed 30 days prior to enrollment. Topical therapy other than steroidal is allowed up to 7 days prior to enrollment * History of adverse events to any ingredients of study medication * Neurological, cardiovascular, respiratory, hepatic, renal, or metabolic disease likely to interfere with the patient's participation in or completion of the study * Arterial or venous disorder resulting in ulcerated wounds * Diabetes mellitus except if disease is determined to be under control with a glycosylated hemoglobin ≤8.5% of total hemoglobin * Pregnancy or breastfeeding during the study. (A serum pregnancy test will be performed at Screening for female patients of childbearing potential.)